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The American Vascular Association/Lifeline Foundation is celebrating its 20th anniversary this year. This remarkable
two-decade journey represents a cumulative effort by the leaders and members of the Society for Vascular Surgery (SVS).
For the historical record, we would like to chart the sequence of events leading to various programs. In 1986, the
Executive Council of SVS approved the formation of an Education/Research Foundation, from which the Lifeline
Foundation evolved, with the mission to support the career development of young research-oriented vascular surgeons.
Since that time, Lifeline has awarded 141 Student Fellowships, 21 Wylie Traveling Fellowships, 17 Mentored Clinical
Scientist Development (K08) Awards, and three Mentored Patient-Oriented Research Career Development (K23)
Awards. In 2001, the American Vascular Association (AVA) was established under the aegis of American Association for
Vascular Surgery (formerly International Society for Cardiovascular Surgery-North American Chapter). In 2004, with
the merger of the SVS and the American Association of Vascular Surgery into a single entity (SVS), Lifeline and the AVA
merged into a single foundation, the AVA. As AVA/Lifeline is poised to launch a campaign for an endowment fund, we
hope this report will let the members of the SVS know what has been accomplished, what we plan to do, and, most
importantly, what we need to do in the future. ( J Vasc Surg 2008;47:1351-5.)Which of the operations we are doing today will be the
discards of the next decade? What is needed is knowledge
and such knowledge will be provided by the young amongst
us and those yet to come.
Allan Callow, 1987
The American Vascular Association (AVA)/Lifeline
Foundation is celebrating its 20th anniversary this year.
This remarkable two-decade journey represents a cumula-
tive effort by the leaders and members of the Society for
Vascular Surgery (SVS). For the historical record, we would
like to chart the sequence of events leading to various
programs. As AVA/Lifeline is poised to launch a campaign
for an endowment fund, we hope this report will let the
members of the SVS know what has been accomplished,
what we plan to do, and, most importantly, what we need
to do in the future.
In the early 1980s, vascular surgeons had become
experts in the surgical treatment of atherosclerosis obliter-
ans. However, fundamental knowledge about atheroscle-
rosis and basic insights into the pathogenesis of neointimal
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search generally consisted of implanting prosthetic devices
in the arterial system and studying patency. Vascular sur-
geons were only beginning to investigate the molecular
biologic mechanisms of vascular disease.
Unfortunately, funding for research at the time was
difficult and discouraged many young investigators. Fur-
thermore, reduction in reimbursement forced many young
surgeons to take up heavy clinical loads to generate incomes
for their academic departments. In 1982, departments of
surgery received only 5.1% of the total National Institutes
of Health (NIH) awards, and this amount was declining. It
also became apparent to the leaders of the SVS that with the
rapid expansion of biologic investigations, dabbling in basic
science research was no longer possible. Basic laboratory
research required a substantial time commitment by young
investigative clinician–scientists to compete with nonsurgi-
cal colleagues. The SVS recognized the need to protect
time for career development and the financial resources
required in the establishment of a charitable foundation.
In 1984, Dr Allan Callow asked the leadership of the
SVS for the “utilization of certain assets of the Society to
further the interests of young surgeons.” The Executive
Council of SVS approved the request and the formation of
a Foundation for Research and Education at the June
meeting in 1986.1 The Board of Directors of the new
foundation met in NewOrleans on October 22, 1986. The
first board members included Drs Victor Bernhard, Allan
Callow, Calvin Ernst, Wesley Moore, and Malcolm Perry.
At this first meeting, officers were elected: Dr Calvin Ernst,
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Malcolm Perry, secretary/treasurer. The foundation’s fi-
nancial support came from a grant of $50,000 from the
SVS, a grant of $10,000 fromW. L. Gore&Associates, and
$4000 in contributions from members of the Board of
Directors.
In 1988, Dr Michael DeBakey became president of the
foundation, and it was registered in Illinois as a 501C(3)
nonprofit charitable foundation. In 1989, the Foundation
for Research and Education adopted a new name—the
Lifeline Foundation—as suggested by Dr DeBakey. The
SVS Council provided $100,000 per year for 5 years to
establish funding for the first award. The leaders of the
Lifeline Foundation then included Drs Michael DeBakey,
Thomas Fogarty, Robert Leather, John Mannick, John
Ochsner, Ronald Stoney, Victor Bernhard, Malcolm Perry,
Allen Callow, Wesley Moore, and Stanley Crawford.1
Dr Calvin Ernst served as executive director of the
Lifeline Foundation for 5 years (1987-1991), creating pro-
grams such as the Industrial Advisory Committee and the
Resident Research Award. The first Resident Research
Award in the amount of $40,000 was given to Dr Brian
Rubin, Washington University, to study the effects of the
duration of thrombosis on vessel wall thrombogenicity.
Acting on the recommendation of Dr Ronald Stoney, the
foundation established an Industrial Advisory Committee
(IAC) to allow participation by industry in the foundation
and to provide a closer liaison between the two groups.
In the 1980s, the landscape of surgical research had
changed significantly and, in many surgical departments,
large animal study had gradually been replaced by molecu-
lar biology or gene-based research. Surgical research re-
quires a close mentorship and exchange between surgeons
and basic scientists. Dr Eugene Strandness first conceived
the idea of a closer liaison of the SVS and International
Society for Cardiovascular Surgery (ISCVS) with the Na-
tional Heart, Lung and Blood Institutes/National Insti-
tutes of Health (NHLBI/NIH). He thought that, if an
interchange of ideas could evolve, it could be important to
those involved in research devoted to vascular disease. With
the help of John Watson, chief of Device and Technology
Brand, and Robert Barnes of the Cardiology Advisory
Committee of NHLBI, a Workshop on Vascular Disease
was established. The success of the workshop resulted in a
publication of the proceedings, Vascular Disease: Current
Research and Clinical Application in 1987.2
Because of the success, a dialogue began with Dr
Claude Lenfant, the director of NHLBI, to plan future
meetings, which became known as the Research Initiatives
Conference. The first joint meeting was held February 19
and 20, 1988, in Bethesda, Maryland. In 1993, the Re-
search Initiatives Conference was incorporated into the
Lifeline Foundation. From 1993 to present, the Research
Initiatives has functioned under the leadership of the Life-
line Foundation/AVA.3 The Research Initiatives Confer-
ence is the only annual research meeting sponsored jointly
by the NIH and a surgical society. Both the NIH and the
scientific community have benefited from this type of ex-change.Manymembers of the SVS have helped to organize
the meetings.
Sponsorship of the meeting is expensive and draining
on the financial resources of the Lifeline Foundation. We
are very fortunate to have received a generous endowment
of $500,000 from Dr and Mrs Julius Jacobson to support
the Research Initiatives meeting. Dr Julius Jacobson, a
well-known vascular surgeon from New York, has made
great contributions in microsurgery and is also known for
his philanthropic activities. On the recommendation of the
Joint Council, the conference was renamed as the Joan and
Julius Jacobson Research Initiatives Conference.4
In 1992, the Council of the ISCVS-North American
Chapter (NA) agreed to match the $50,000 support from
SVS for 5 years for equal representation on the Lifeline
Foundation Board. The inclusion of the ISCVS increased
the number of the Board of Directors to include represen-
tation from the ISCVS. The inclusion of the ISCVS in the
Lifeline Foundation also was associated with the transfer of
the Student Fellowship Research Award to the foundation.
The Student Fellowship Research Award is intended to
stimulate the interest of students to choose vascular surgery
as a career. The award consists of $3000 funding to allow
the student to work in the laboratory or on a project under
the mentorship of an SVS member. About 10 students
receive the award every year, and 141 awards have been
given since its inception.
In 1992, the Lifeline Foundation also assumed admin-
istrative responsibility of the E. J. Wylie Traveling Fellow-
ship. The idea was originated in the summer of 1984 byDrs
John Bergan and James Yao. The fellowship allows young
surgeons to visit centers of excellence in research or clinical
surgery to broaden their horizons in surgery and also to
provide them with personal contacts with leaders or re-
searchers in vascular surgery at home or abroad. Dr Peter
Gloviczki was the first E. J. Wylie Traveling Fellow and
described the spirit of the Fellowship by saying, “I traveled
on the shoulder of a giant.”5 We are grateful for the
generous support from W. L. Gore & Associates (Jack
Hoover and Donald Lass). Many of the E. J. Wylie Travel-
ing Fellows went on to become leaders of national, re-
gional, or local vascular societies (Table I).
In May 1993, the logo of the Lifeline Foundation,
designed by Dr Ernst, was adopted under President Eu-
gene Strandness. During the summer of 1993, the officers
of the foundation requested support from the regional
societies. The regional societies were supportive and pro-
vided funds ranging from $10,000 to $50,000. From 1991
to 1996, Dr Ronald Stoney was the executive director. In
1994, the mission of the Lifeline Foundation was formal-
ized to support research and education in vascular dis-
ease by:
1. enhancing the development of young surgical scientists
in the advancement of vascular science through its com-
prehensive research funding commitment, and
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treatment, and prevention of vascular disease is dissem-
inated to the medical profession and to the public.
Dr John Mannick assumed the presidency of the Life-
line Foundation in 1996-1997. During the first year of his
leadership, the foundation was restructured to make it
more responsive to the needs of its constituencies. Four
new members from industry were added; all had voting
privileges on the foundation. In addition, Dr James Yaowas
asked to serve as the vice president for Development, and
liaisons from the NHLBI, David Robinson, and for clinical
investigations, Dr Rodney White, were added.
In the early 1990s, NIH developed the Mentored
Clinical Scientist Development (K08) Award to help sup-
port career development in laboratory-based basic and
translational research for clinically trained individuals. Dr
Yao worked with Mr Robinson to develop a partnership
support for a K08 grant. The meeting with Robinson led to
a visit to NHLBI Director Dr Claude Lenfant at Bethesda
in 1997 by Drs Alexander Clowes, James Yao, and John
Mannick. The presence of Dr Clowes, a well-known re-
searcher with NIH funding, impressed upon Dr Lenfant
that vascular surgeons indeed are serious about pursuing
basic science research. Dr Lenfant agreed to the partner-
ship, making this a landmark event for the Lifeline Foun-
dation and for vascular surgery. For the first time, the NIH
partnered with a surgical society for sponsorship of a K08
grant.
During this same interval, Dr Mannick proposed to the
William J. von Liebig Foundation funding of these K08
grants. Working with Linda Hamilton of the von Liebig
Foundation, a memorandum of understanding was com-
Table I. E. J. Wylie Traveling Fellowship, 1987-1988 to
2007-2008
Year of award Recipient
1987-1988 Peter Gloviczki, MD
1988-1989 Torben Schroeder, MD
1989-1990 Alan M. Graham, MD
1990-1991 Bauer E. Sumpio, MD
1991-1992 Thomas F. Panetta, MD
1992-1993 Julie A. Freischlag, MD
1993-1994 Joseph L. Mills, MD
1994-1995 K. Craig Kent, MD
1995-1996 B. Timothy Baxter, MD
1996-1997 Elliot L. Chaikof, MD, PhD
1997-1998 Peter J. Pappas, MD
1998-1999 Richard J. Powell, MD
1999-2000 Steven M. Santilli, MD, PhD
2000-2001 Ronald L. Dalman, MD
2001-2002 C. Keith Ozaki, MD
2002-2003 Alan Dardik, MD, PhD
2003-2004 Jon S. Matsumura, MD
2004-2005 David C. Cassada, MD
2005-2006 Mark K. Eskandari, MD
2006-2007 Joseph J. Giglia, MD
2007-2008 Luis R. Leon Jr, MD, RVTpleted and signed in November 1998. The award wasrenamed The William J. von Liebig Mentored Clinical
Scientist Development Award and is given to two investi-
gators per year with funding support of $150,000 per
investigator per year for 5 years. Since 1999, the Lifeline
Foundation has given 17 von Liebig awards to vascular
surgeons. Table II lists the names of the recipients and titles
of their research projects.
Dr Robert Thompson recently reviewed the outcome
of von Liebig award recipients and found six of seven (86%)
vascular surgeons holding the K08 over 3 years had re-
ceived academic promotion with tenure. All five who had
completed the 5-year award had achieved independent
investigator status with NIH support, showing that the von
Liebig K08 program is an effective vehicle to stimulate
research career development in the field of vascular sur-
gery.6 Multiple factors contribute to this success:
1. the combined funding fromLifeline andNHLBI is large
enough that the award recipients do not need to have a
heavy clinical load to generate income for salary;
2. the recipient is able to spend time with the mentor, a
basic research scientist, to learn all the necessary molec-
ular- or gene-based techniques to be an independent
investigator; and,
3. the exposure to the basic science research environment
helps to shape the careers of the recipients.
To allow Canadian surgeons to have equal access to the
award, a memorandum of understanding has been signed
with the Canadian Medical Council.
The Lifeline Foundation Board of Directors initiated
the Technology Assessment Committee, which was de-
signed to evaluate emerging technology. This, in conjunc-
tion with the Industrial Advisory Committee and the En-
dovascular Steering Committee, formed the nucleus of
activities that led to the development of a registry to eval-
uate endovascular grafts. The Lifeline Endovascular Graft
Registry project was begun in 1997 and was led by Dr
Rodney White. The Endovascular Graft Registry recruited
funding for a robust project to evaluate United States Food
and Drug Administration (FDA)–approved endovascular
devices. The registry was administered by the New England
Research Institute under a contract to the Lifeline Founda-
tion. The registry collected data on 2664 patients with
endovascular grafts implanted and 334 open surgical pa-
tients. The report on long-term primary outcome measures
of the Lifeline registry of endovascular aneurysm repair was
recently published in the Journal of Vascular Surgery.7,8
The registry data suggest endovascular graft repair using
FDA-approved devices is safe, effective, and durable. Need-
less to say, endovascular graft repair has since changed the
face of practice in vascular surgery—nearly 50% of cases are
now done with endovascular technology.
In 1999, an anonymous donor provided a $3 million
challenge-matching grant to the Lifeline Foundation as an
endowment for clinical research. The donor would give the
first $1 million, and if the SVS matched the same amount,
the donor would give an additional $1 million to make a
corpus $3 million endowment. Dr James Yao began an
ular s
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and local societies, and industry partners to match the
$1 million Challenge Grant. The campaign raised nearly
$700,000 and, with the remaining funds from the founda-
tion to make it $1 million, the $3 million endowment was
achieved. The details of the endowment were that a corpus
of $3million was required before interest could be spent on
funding awards. The endowment by the anonymous donor
reinforces that the American spirit of philanthropy is still
alive. We salute the generosity and foresight of this individ-
ual. As new technology emerges, there is a great need for
competent clinical investigators to evaluate new devices,
and this grant helps to make the training of these investi-
gators a reality.
In 2001, a separate foundation under the aegis of
American Association for Vascular Surgery (formerly
ISCVS-NA) was established with Dr Robert Hobson as the
president. The name of the foundation was American Vas-
cular Association (AVA), modeled after American Heart or
Stroke Association. The primary mission of AVA is to
promote public education and community outreach. Two
early AVA initiatives included the Vascular Screening Pro-
gram spearheaded by Dr William Flinn and the American
Vascular Research Organization (AVRO) headed by Dr
John Blebea. The idea behind AVRO was to provide a
single source for industry to identify programs to conduct
clinical research activities. A third initiative was an AVA
Table II. Lifeline Foundation/National Heart, Lung and
Scientist Development (K08) Awards, 1999 to 2007
Year of award Recipient
1999 Michael S. Conte, MD Gene
1999 Larry W. Kraiss, MD Cont
2000 C. Keith Ozaki, MD Infla
2000 Rajabrata Sarkar, MD, PhD Nitri
2001 Mark G. Davies, MD, PhD uPA
2001 Gilbert R. Upchurch Jr, MD MM
2002 Raul J. Guzman, MD Bone
2002 Peter K. Henke, MD Thro
2003 Peter L. Faries, MD Meas
2003 Paul J. Gagne, MD Colla
2004 Scott A. Berceli, MD, PhD Mech
2004 Darren B. Schneider, MD Role
2005 Paul J. DiMuzio, MD A tis
2005 Iraklis I. Pipinos, MD Mito
2006 Alan Dardik, MD Flow
2006 Melina R. Kibbe, MD Nitri
2007 John A. Curci, MD Vasc
Table III. American Vascular Association/Lifeline/Natio
Patient-Oriented Research Career Development Award (K
Year of award Recipient
2005 Gregory J. Landry, MD
2006 Matthew S. Edwards, MD
2007 Vikram S. Kashyapcomponent to provide public education on the VascularWeb. These programs were supported by industry partners
and individuals.
In 2003, Dr James Yao succeeded Dr John Mannick as
president of the Lifeline Foundation. Shortly afterwards, he
received a letter from Dr Claude Lenfant of NHLBI/NIH
inviting Lifeline to form a joint partnership for a K23 grant
similar to that of the K08, except that this grant would be
designated for clinical investigators. The K23 award is
intended to support the career development of investiga-
tors who have made a commitment to focus their research
endeavors on patient-oriented research. Patient-oriented
research is defined as research conducted with human
subjects and includes (1) mechanisms of human disease,
(2) therapeutic intervention, (3) clinical trials, and (4) the
development of new technologies. With the approval of the
SVS Council, a memorandum of understanding was com-
pleted with NHLBI. The first K23 award was given to Dr
Gregory Landry in 2005 to study functional outcome of
critical limb ischemia. Table III lists the award recipients
and titles of K23 awards given by the Lifeline Foundation.
During the tenure of Dr James Yao, the Lifeline Exec-
utive Committee took several actions. These included (1) a
review of the Endovascular Registry by a special committee,
(2) a review of the performance of the investment firm and
its policies, and (3) a decision to provide joint funding of
the von Liebig Resident Research Award to be presented at
the Southern Vascular Society meeting. The review of the
d Institute William J. von Liebig Mentored Clinical
Research project
gineering of a failure resistant vein graft
f endothelial translation by fluid shear stress
ory mechanisms of neointimal hyperplasia
e and smooth muscle cell proliferation
tor signaling and cell migration
ependent vessel wall remodeling is NO dependent
phogenetic proteins in arterial remodeling
resolution is CXC chemokine dependent
the efficacy of endovascular treatment of AAA
IV remodeling in ischemic leg revascularization
s of shear-regulated vein graft remodeling
ogenitor cells in hindlimb revascularization
gineered, small diameter vascular graft
driopathy of chronically ischemic muscle
nses to carotid angioplasty
e eluting therapies for vascular surgery
mooth muscle cells and elastolysis in abdominal aortic aneurysms
eart, Lung and Blood Institute Mentored
2005 to 2007
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Functional outcome of critical limb ischemia
Embolic protection during renal artery stenting
Endothelial function in human peripheral arteriesBloo
tic en
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23),financial status of Lifeline led to a change of management
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a portfolio change to ensure diversity of the investment.
The Challenge Grant experienced a significant loss in 1999
as a result of the stock crash. Since the new investment firm
and strategy have been in place, it has more than $3 million
in assets.
One of the major events in 2004 was the merger of the
SVS and the American Association of Vascular Surgery into
a single entity, the Society for Vascular Surgery (SVS). With
the merger, it was not desirable to have two foundations,
and on the advice of the SVS Executive Council, Lifeline
and AVA merged into a single foundation, the American
Vascular Association (AVA). All programs under the Life-
line Foundation will retain the name Lifeline.
In 2004, Dr William Pearce became the new leader of
AVA, and both Drs Hobson and Yao were named emeritus
members on the board to ensure a smooth transition.
Under the direction of Dr Pearce, several programs such as
the screening program, ARVO, and the Endovascular Reg-
istry have been moved to SVS.
One of the most disappointing things we have to report
is the loss of support of the von Liebig Foundation for the
K08 grant. We are grateful for the generous support of the
von Liebig Foundation in the past. In the last two decades,
the von Liebig Foundation has been the main support for
research under the direction of the Lifeline Foundation,
and we have received a total of $6million for the K08 grant,
an unprecedented amount of funds. The loss of von Liebig
support means we needed to chart new ways to support the
K08 and K23 grants. The AVA has forged relationships
with the American College of Surgeons to help support
research. The American College of Surgeons, with the
input of Dr Clowes, established a scholarship program for
all surgeons that will support $37,500 of a K08 award. This
year, Dr John Curci received both the AVA award of
$37,500 and the American College of Surgeons award of
$37,500.
As we look back over the last two decades, we should be
proud of what the Lifeline Foundation has accomplished.
We are not the only surgical society that has an annual
meeting with NHLBI/NIH, but we are the first surgical
society to have a partnership with NIH to develop surgeon-
scientists and clinical investigators. Reading the recent sup-
plemental issue of the Journal of Vascular Surgery, “Cur-
rent Topics in Clinical and Basic Vascular Research,”8 onehas to be impressed with the depth and the breadth of the
research by young vascular surgeons. There are 19 studies
covering a wide variety of vascular biology mechanisms in
vascular problems, and all are written by recipients of K08
and K23 grants.
In addition, the Lifeline Foundation supports student
research fellowships, the E. J. Wylie Traveling Fellowship,
and the Resident Research Award. We need to remind
ourselves that the commitment of a foundation is the
pursuit of research support. The success we have is a cumu-
lative effort by many leaders and members too numerous to
list in this report.
Although we appear to be very successful, we must not
stop, especially since we lost the funding support from the
von Liebig Foundation. We need to continue to support
basic science research to answer the question raised in the
quotation by Dr Allan Callow at the beginning of this
article. The next phase of the Lifeline Foundation efforts is
to launch a fund-raising campaign for an endowment fund
to support the K08 and K23 grants. Philanthropy is an
American spirit, and to keep the spirit alive, we urge all
members to continue to give to the AVA/Lifeline Foun-
dation. As Winston Churchill said, “We make a living by
what we get, but we make a life by what we give.”
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